Titre :

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Auteur(s) :

Ginsberg, Henry [Auteur correspondant]
Columbia University [New York]
Packard, Chris [Auteur]
University of Glasgow
Chapman, M. John [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Borén, Jan [Auteur]
Göteborgs Universitet = University of Gothenburg [GU]
Sahlgrenska University Hospital [Gothenburg]
Aguilar-Salinas, Carlos [Auteur]
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán - National Institute of Medical Science and Nutrition Salvador Zubiran [Mexico]
Tecnológico de Monterrey = Monterrey Institute of Technology [ITESM]
Averna, Maurizio [Auteur]
Università degli studi di Palermo - University of Palermo
Ference, Brian [Auteur]
University of Cambridge [UK] [CAM]
Gaudet, Daniel [Auteur]
Université de Montréal [UdeM]
Hegele, Robert [Auteur]
Schulich School of Medicine and Dentistry
Kersten, Sander [Auteur]
Wageningen University and Research [Wageningen] [WUR]
Lewis, Gary [Auteur]
University of Toronto
Lichtenstein, Alice [Auteur]
Tufts University School of Medicine [Boston]
Moulin, Philippe [Auteur]
Cardiovasculaire, métabolisme, diabétologie et nutrition [CarMeN]
Nordestgaard, Børge [Auteur]
Copenhagen University Hospital
University of Copenhagen = Københavns Universitet [UCPH]
Remaley, Alan [Auteur]
National Institutes of Health [Bethesda, MD, USA] [NIH]
Staels, Bart [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Stroes, Erik [Auteur]
Academic Medical Center - Academisch Medisch Centrum [Amsterdam] [AMC]
Taskinen, Marja-Riitta [Auteur]
Helsingin yliopisto = Helsingfors universitet = University of Helsinki
Tokgözoğlu, Lale [Auteur]
Hacettepe University = Hacettepe Üniversitesi
Tybjaerg-Hansen, Anne [Auteur]
Rigshospitalet [Copenhagen]
Herlev and Gentofte Hospital
University of Copenhagen = Københavns Universitet [UCPH]
Stock, Jane [Auteur]
European Atherosclerosis Society [Göteborg, Sweden] [EAS]
Catapano, Alberico [Auteur]
Università degli Studi di Milano = University of Milan [UNIMI]

Titre de la revue :

European Heart Journal

Pagination :

ehab551

Éditeur :

Oxford University Press (OUP)

Date de publication :

2021-09-02

ISSN :

0195-668X

Mot(s)-clé(s) en anglais :

Triglycerides
Triglyceride-rich lipoproteins
Lipoprotein remnants
Cardiovascular disease
Residual risk

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Endocrinologie et métabolisme

Résumé en anglais : [en]

Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins ...
Lire la suite >Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo-and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011

Source :

Harvested from HAL